resTORbio vs Juvenescence

resTORbio was a mTOR-pathway geroscience pioneer developing RTB101 to target age-related disease; after its lead Phase 3 trial failed, it reverse-merged into Adicet Bio in 2020 and abandoned its aging program.

AI-enabled longevity drug company and holding group building a pipeline of medicines to extend healthy human lifespan.